Sinqi Pharmaceutical (300573.SZ): participants enrolled in the first phase Ia clinical trial of SQ-23101 injection to treat thyroid eye disease

Zhitongcaijing · 23h ago

According to Zhitong Finance App News, Sinqi Pharmaceutical (300573.SZ) announced that the SQ-23101 injection developed by the company recently completed the first “Phase Ia clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of SQ-23101 injection in patients with thyroid eye disease”.

The phase Ia study of SQ-23101 injection for thyroid eye disease was a multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the safety and tolerability of a single dose of SQ-23101 injection in patients with thyroid eye disease, and to evaluate the pharmacokinetic (PK) characteristics, immunogenicity, pharmacodynamics (PD) characteristics and clinical efficacy of a single dose.